

FAX TRANSMISSION**DATE:** October 15, 2008**PTO IDENTIFIER:** Application Number 10/594,773-Conf. #3641
Patent Number**Inventor:** Hiroshi Inooka et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** EDWARDS ANGELL PALMER & DODGE LLP

Gregory B. Butler, Ph.D., Esq.

PHONE: (617) 517-5595**Attorney Dkt. #:** 66368(46590)**PAGES (Including Cover Sheet):** 4**CONTENTS:** Certificate of Transmission (1 page)
Response to Restriction Requirement (without Traverse) (2 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 517-5595 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874, Boston, Massachusetts 02205
Telephone: (617) 239-0100 **Facsimile:** (617) 227-4420

OCT 15 2008

PTO/SB/97 (08-04)

Approved for use through 07/31/2008. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Application No. (if known): 10/594,773

Attorney Docket No.: 66368(46590)

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on October 15, 2008
Date



Signature

Lynn Marcus

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 239-0100

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Response to Restriction Requirement (without Traverse) (2 page)

RECEIVED
CENTRAL FAX CENTER

OCT 15 2008

Docket No.: 66368(46590)
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
Hiroshi Inooka et al.

Application No.: 10/594,773

Confirmation No.: 3641

Filed: September 29, 2006

Art Unit: 1646

For: ANTIBODY DRUG

Examiner: Ruixiang Li

RESPONSE TO RESTRICTION REQUIREMENTMS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed September 23, 2008, Applicant hereby provisionally elects **GLP-1** in claim 10 as an endogenous ligand and "**metabolic disease**" in claim 15 as a target disease, without traverse.

The afore-mentioned election is being made solely to comply with, and be fully responsive to, the restriction requirement set forth in the Office Action. The right to file one or more divisional applications on non-elected subject matter is reserved.

Additionally, Applicant reserves the right to pursue rejoinder of withdrawn process claims that depend from or otherwise include all the limitations of an allowable product claim.

Early and favorable examination is requested.